The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Mar. 10, 2020

Filed:

Mar. 10, 2016
Applicant:

Wavesense, Inc., Irvine, CA (US);

Inventor:

Christopher Feistel, Irvine, CA (US);

Assignee:

WAVESENSE, INC., Irvine, CA (US);

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61B 5/00 (2006.01); G01N 33/574 (2006.01); A61K 31/58 (2006.01); C12Q 1/6886 (2018.01); A61B 17/00 (2006.01); A61B 18/00 (2006.01);
U.S. Cl.
CPC ...
G01N 33/57434 (2013.01); A61K 31/58 (2013.01); A61B 2017/00274 (2013.01); A61B 2018/00547 (2013.01); C12Q 1/6886 (2013.01);
Abstract

Disclosed are methods to induce dislodgement of target prostatic cells from the prostate organ, collecting said cells, and subsequently examining the cell population. Such methods comprise the administration of an agent that facilitates the dislodgement of the target cells from within the prostate, which then migrate into the urethra. Exemplary agents include 5 alpha-reductase inhibitors. The cells induced to pass into the urethra are then collected non-invasively, such as through urine or semen samples. Such collection is further strategically calculated relative the administration of the agent so as to maximize the sample collection of the target cells of interest. The exfoliated prostatic epithelial cells are subsequently utilized for purposes such as detecting prostate cancer, predicting/measuring prostate tumor susceptibility to drug regimes, active surveillance of patients whose prostate biopsy results are negative, but continue to exhibit symptoms consistent with prostate cancer, and identifying false positive results associated with biomarker assays.


Find Patent Forward Citations

Loading…